Full Text | PDF

Share on tweeters Share on facebook Share on linkedin Share on googleplus

Int J Biol Sci 2023; 19(15):5020-5035. doi:10.7150/ijbs.87964 This issue Cite

Review

Targeting HMGB1: A Potential Therapeutic Strategy for Chronic Kidney Disease

Tongtong Liu1#, Qian Li1#, Qi Jin1, Liping Yang1, Huimin Mao1, Peng Qu2, Jing Guo3, Bo Zhang2, Fang Ma1, Yuyang Wang1, Liang Peng2✉, Ping Li2✉, Yongli Zhan1✉

1. Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
2. China-Japan Friendship Hospital, Institute of Medical Science, Beijing, China.
3. Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China.
# co-author: Tongtong LIU and Qian LI contributed equally to the article.

✉ Corresponding authors: pengliang8028com (L. PENG); lp8675com (P. LI) and zhanyongli88com (Y. ZHAN).

Citation:
Liu T, Li Q, Jin Q, Yang L, Mao H, Qu P, Guo J, Zhang B, Ma F, Wang Y, Peng L, Li P, Zhan Y. Targeting HMGB1: A Potential Therapeutic Strategy for Chronic Kidney Disease. Int J Biol Sci 2023; 19(15):5020-5035. doi:10.7150/ijbs.87964. https://www.ijbs.com/v19p5020.htm
Other styles

File import instruction

Abstract

Graphic abstract

High-mobility group protein box 1 (HMGB1) is a member of a highly conserved high-mobility group protein present in all cell types. HMGB1 plays multiple roles both inside and outside the cell, depending on its subcellular localization, context, and post-translational modifications. HMGB1 is also associated with the progression of various diseases. Particularly, HMGB1 plays a critical role in CKD progression and prognosis. HMGB1 participates in multiple key events in CKD progression by activating downstream signals, including renal inflammation, the onset of persistent fibrosis, renal aging, AKI-to-CKD transition, and important cardiovascular complications. More importantly, HMGB1 plays a distinct role in the chronic pathophysiology of kidney disease, which differs from that in acute lesions. This review describes the regulatory role of HMGB1 in renal homeostasis and summarizes how HMGB1 affects CKD progression and prognosis. Finally, some promising therapeutic strategies for the targeted inhibition of HMGB1 in improving CKD are summarized. Although the application of HMGB1 as a therapeutic target in CKD faces some challenges, a more in-depth understanding of the intracellular and extracellular regulatory mechanisms of HMGB1 that underly the occurrence and progression of CKD might render HMGB1 an attractive therapeutic target for CKD.

Keywords: HMGB1, CKD, renal homeostasis, AKI-to-CKD transition, therapeutic strategy

Citation styles

APA
Liu, T., Li, Q., Jin, Q., Yang, L., Mao, H., Qu, P., Guo, J., Zhang, B., Ma, F., Wang, Y., Peng, L., Li, P., Zhan, Y. (2023). Targeting HMGB1: A Potential Therapeutic Strategy for Chronic Kidney Disease. International Journal of Biological Sciences, 19(15), 5020-5035. https://doi.org/10.7150/ijbs.87964.

ACS
Liu, T.; Li, Q.; Jin, Q.; Yang, L.; Mao, H.; Qu, P.; Guo, J.; Zhang, B.; Ma, F.; Wang, Y.; Peng, L.; Li, P.; Zhan, Y. Targeting HMGB1: A Potential Therapeutic Strategy for Chronic Kidney Disease. Int. J. Biol. Sci. 2023, 19 (15), 5020-5035. DOI: 10.7150/ijbs.87964.

NLM
Liu T, Li Q, Jin Q, Yang L, Mao H, Qu P, Guo J, Zhang B, Ma F, Wang Y, Peng L, Li P, Zhan Y. Targeting HMGB1: A Potential Therapeutic Strategy for Chronic Kidney Disease. Int J Biol Sci 2023; 19(15):5020-5035. doi:10.7150/ijbs.87964. https://www.ijbs.com/v19p5020.htm

CSE
Liu T, Li Q, Jin Q, Yang L, Mao H, Qu P, Guo J, Zhang B, Ma F, Wang Y, Peng L, Li P, Zhan Y. 2023. Targeting HMGB1: A Potential Therapeutic Strategy for Chronic Kidney Disease. Int J Biol Sci. 19(15):5020-5035.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2024 Ivyspring International Publisher. Terms of use